Working Groups

The WG for AllergoOncology is a hard-working group of enthusiastic academic and clinical experts in both, allergy and cancer with an innovative interdisciplinary agenda, driving novel ideas that link Allergy with several disciplines, for the benefit of patients and overall contributing to the research and translational aspirations and originality of EAACI.

The EAACI AllergoOncology group was founded as a Task Force in 2014 within the Basic Immunology Section to investigate the unique immunologic interface between allergy, IgE immune responses and oncology. Today, the AllergoOncology WG itself comprises 4 strong Task Forces with each a unique agenda.

One key area of interest stems from observations that high IgE levels in atopic individuals are associated with lower prevalence of some tumour types. Also, whilst immune tolerance is not desired in cancer, IgE-mediated immune surveillance targeted to cancer cells, might be. The world´s first clinical trial of a recombinant anti-cancer IgE in the UK is pioneered by members of the AllergoOncology group.

The AllergoOncology Task Force during a workshop in Vienna (November 2019) which was dedicated to the preparation of the group’s third position paper by Untersmayr E et al.; Allergy; 2019; AllergoOncology: Microbiota in allergy and cancer.

The AllergoOncology WG board at the EAACI Annual Congress held in Prague (July 2022).

• TF1: AllergoOncology in the Era of Personalized, Stratified and Precision Medicine
  Chair: Aurelie Poli, Secretary: Michelle Turner.
• TF2: Macrophage role in Allergy and Cancer: Novel therapeutic opportunities
  Chair:  Elena Izquierdo; Secretary: Rodolfo Bianchini. (link to the KH TF section)
• TF3: Granulocytes (mast cells, basophils, neutrophils and eosinophils): Understanding their roles in allergy and tumor immunity
  Chair: Mariona Pascal, Secretary: Sophia Karagiannis. (link to the KH TF section)
• TF4: E-learning material about AllergoOncology
  Chair: Leticia de las Vecillas. Secretary: Daniela Carvalho.
  
• Allergooncology webinar based on the 1st Symposium talks, held online on November 2021: Watch it here on the EAACI Knowledege hub.

• Bergmann C, et al. AllergoOncology: Danger signals in Allergology and Oncology. A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2022 Sep;77(9):2594-2617. https://pubmed.ncbi.nlm.nih.gov/35152450/
  Here you can find a resume video about this innovative PP: https://www.youtube.com/watch?v=i85j3e-aIrw&ab_channel=Allergy
• Ferastraoaru D, et al. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer – a position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clinical Translational Allergy, 2020 Jul 17;10:32. doi: 10.1186/s13601-020-00335-w. https://pubmed.ncbi.nlm.nih.gov/32695309/
• Untersmayr E, et al. AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper. Allergy, 2019 Jun;74(6):1037-1051. https://pubmed.ncbi.nlm.nih.gov/30636005/
• Jensen-Jarolim E, et al. AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer. EAACI Position paper. Allergy. 2018 Feb;73(2):328-340. doi:10.1111/all.13311. https://pubmed.ncbi.nlm.nih.gov/28921585/
• Jensen-Jarolim E, et al.. AllergoOncology – The impact of Allergy in Oncology. EAACI Position Paper. Allergy. 2017 Jun;72(6):866-887.doi:10.1111/all.13119. https://pubmed.ncbi.nlm.nih.gov/28032353/
• Jensen-Jarolim, E et al. 2008. AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy 2008 Oct;63(10):1255-66. doi:10.1111/j.1398-9995.2008.01768.x. https://pubmed.ncbi.nlm.nih.gov/18671772/

• The first ever clinical trial of an IgE class of immunotherapy for cancer has shown promising results that could benefit patients: https://www.nature.com/articles/s41467-023-39679-9
• Study from the AllergoOncology Working Group researchers uncovers how B cells react to skin cancerLink :
  https://www.nature.com/articles/s41467-023-39042-y
• Manuscript from the AllergoOncology Working Group describing the anti-cancer effects of an IgE class antibody targeting melanoma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130092/pdf/41467_2023_Article_37811.pdf
• Recent paper about the impact of Allergic airway inflammation on glioblastoma progression:

https://pubmed.ncbi.nlm.nih.gov/36210648/

• Video abstract: https://www.youtube.com/watch?v=gi9vC1_OwPY
• Relationship between low serum immunoglobulin E levels and malignancies in 9/11 World Trade Center responders. https://www.annallergy.org/article/S1081-1206(22)00598-1/fulltext
• Clinical and Translational Significance of Basophils in Patients with Cancer. https://www.mdpi.com/2073-4409/11/3/438/htm
• IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1880687
• Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. https://jitc.bmj.com/content/9/6/e002140.long
• AllergoOncology: Role of immune cells and immune proteins. https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12133
• Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy. https://www.frontiersin.org/articles/10.3389/fonc.2022.871390/fullIncreased Hazard Risk of First Malignancy in Adults with Undetectable Serum IgE: a Retrospective Cohort Study. https://link.springer.com/article/10.1007/s10875-022-01401-7
• Generation and Characterization of Native and Sialic Acid-Deficient IgE. https://www.mdpi.com/1422-0067/23/21/13455